CLINICAL TRIALS PROFILE FOR SANCUSO
✉ Email this page to a colleague
All Clinical Trials for SANCUSO
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00186628 ↗ | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-06-01 | To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD) |
NCT00186628 ↗ | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | Completed | The Leukemia and Lymphoma Society | Phase 2 | 2005-06-01 | To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD) |
NCT00186628 ↗ | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | Completed | Stanford University | Phase 2 | 2005-06-01 | To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD) |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SANCUSO
Condition Name
Condition Name for SANCUSO | |
Intervention | Trials |
Chemotherapy Induced Nausea and Vomiting | 3 |
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV) | 2 |
Chemotherapy-induced Nausea and Vomiting (CINV) | 2 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for SANCUSO
Trials by Country
Clinical Trial Progress for SANCUSO
Clinical Trial Phase
Clinical Trial Sponsors for SANCUSO
Sponsor Name